#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pelizaeus-Merzbacher disease Neurodevelopmental disorder Aspergillus infection Orthostatic hypotension B-cell lymphoma Malignant fibrous histiocytoma Urea cycle disorder Giant cell tumour of tendon sheath Central nervous system neoplasm Turner's syndrome Diabetes insipidus Small intestine adenocarcinoma Epidermolysis bullosa Adrenoleukodystrophy B-cell small lymphocytic lymphoma refractory More trials…

    Learn about Rare Diseases

    Chronic granulomatous disease – Basic Information Biotinidase deficiency – Diagnostics Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Marfan’s syndrome – Basic Information Pituitary-dependent Cushing’s syndrome – Basic Information Bronchopulmonary dysplasia – Life with Disease Osteosarcoma metastatic – Basic Information Glycogen storage disease type I – Treatment Alport’s syndrome – Diagnostics Combined immunodeficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Atezolizumab ASP3082 Interferon Beta-1B Gs-5718-03 Tasquinimod Efepoetin Alfa Emraclidine Cefoxitin Sodium Ponatinib Ciclosporin A Cagrilintide Emedastine Sodium Iodide (131I) Cholesterol BRENSOCATIB Ifezuntirgene Inilparvovec Obefazimod Bendamustine Methionine Migalastat More therapies…

    Learn about Your Condition

    Thyroid disorder Actinic keratosis Neuroblastoma Eructation Renal cell carcinoma Lung transplant rejection Hyperglycaemia Muscle hypertrophy Infant sedation Lumbosacral radiculopathy Reperfusion injury Marfan's syndrome Sinusitis bacterial Laryngeal leukoplakia Short-bowel syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • S-241656
    • Cetuximab
    • Fluorouracil
    Denmark France Italy Spain

  • A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sodium Chloride
    Belgium France Germany Italy The Netherlands Spain

  • A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Ipilimumab
    Germany Spain

  • A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

    Recruiting

    3 1
    Investigated Diseases:
    • Obesity
    • Overweight
    Investigated Drugs:
    • LY3841136 SODIUM
    Belgium Czechia Romania Spain

  • A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Acalabrutinib
    • Venetoclax
    Czechia France Germany Italy The Netherlands Poland +3

  • A study comparing mifamurtide to sorafenib for treating high-risk osteosarcoma in children and young adults

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteosarcoma
    Investigated Drugs:
    • Mifamurtide
    • Sorafenib
    Poland
Previous Page
1 … 26 27 28 29 30 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!